Distalmotion Secures $150M to Expand Robotic Surgery Platform in U.S. Outpatient Market

• Distalmotion closed a $150 million Series G round led by Revival Healthcare Capital to scale the U.S. rollout of its soft tissue robotic surgery system.
• The company cites growing demand in ambulatory surgical centers and recent FDA clearance in gynecology as key drivers.

Distalmotion, a MedTech company based in Lausanne, announced the closing of a $150 million Series G funding round led by Revival Healthcare Capital. The funding will accelerate U.S. commercialization of its robotic surgery system and support clinical and product development.

Its soft tissue robotic surgery system, DEXTER, is designed to simplify operations and bring wristed robotics to any operating room. The system includes fully wristed single-use instruments, a sterile console that allows surgeons to remain bedside, and a compact, mobile design compatible with any size operating room. Its open architecture enables integration with a range of existing visualization systems and devices, while its intuitive design supports efficient learning and use.

According to Distalmotion, DEXTER has been adopted in clinical practice across Europe and the U.S., treating nearly 3,000 patients. With recent FDA clearance in gynecology and product enhancements, the company continues to prioritize expansion in the Ambulatory Surgery Center (ASC) market, which it describes as one of the fastest-growing segments in surgical care.

🌀 Tom’s Take:

ASCs are fast-growing outpatient centers. Distalmotion is betting that DEXTER’s speed and portability make it a strong fit for these cost-sensitive surgical settings.

Source: GlobeNewswire / Distalmotion